Stock ScreenerStock IdeasZen Ratings + Top AnalystsStocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: Sep 7, 2025The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.
Stock ScreenerStock IdeasZen Ratings + Top Analysts
Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
| Ticker | Company | Exchange | Industry | Zen Rating | Market Cap | Price | 1d % | EBITDA | P/E | D/E | Country | DD Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | NYSE | Drug Manufacturers - General | A | $688.27B | $727.21 | -2.11% | $18.75B | 47.38x | 4.52 | United States | 65 |
| RYAAY | RYANAIR HOLDINGS PLC | NASDAQ | Airlines | A | $32.19B | $60.51 | 0.36% | $3.44B | 18.40x | 1.49 | Ireland | 37 |
| WIX | WIXCOM LTD | NASDAQ | Software - Infrastructure | A | $8.56B | $153.10 | 4.04% | $173.72M | 51.20x | -17.96 | Israel | 38 |
| BGC | BGC GROUP INC | NASDAQ | Capital Markets | A | $4.71B | $9.94 | -0.50% | $404.32M | 32.06x | 4.07 | United States | 45 |
| IHS | IHS HOLDING LTD | NYSE | Telecom Services | A | $2.44B | $7.27 | 0.97% | N/A | 21.38x | -16.94 | United Kingdom | 25 |
| DBD | DIEBOLD NIXDORF INC | NYSE | Software - Application | A | $2.19B | $59.90 | 0.27% | $275.40M | -176.18x | 2.40 | United States | 17 |
| FIVN | FIVE9 INC | NASDAQ | Software - Infrastructure | A | $2.06B | $26.70 | 1.52% | $98.42M | 205.38x | 1.38 | United States | 46 |
| ARDT | ARDENT HEALTH PARTNERS INC | NYSE | Medical Care Facilities | A | $1.88B | $13.16 | 2.33% | $541.00M | 7.08x | 2.70 | United States | 48 |
| NTCT | NETSCOUT SYSTEMS INC | NASDAQ | Software - Infrastructure | A | $1.77B | $24.86 | -0.76% | -$294.85M | -4.86x | 0.40 | United States | 28 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | NASDAQ | Biotechnology | A | $1.74B | $8.27 | 0.00% | $63.44M | -45.94x | -2.08 | United States | 12 |
| AVDL | AVADEL PHARMACEUTICALS PLC | NASDAQ | Drug Manufacturers - Specialty & Generic | A | $1.53B | $15.76 | 5.14% | $7.86M | -525.33x | 1.06 | Ireland | 35 |
| GBX | GREENBRIER COMPANIES INC | NYSE | Railroads | A | $1.46B | $47.16 | 0.30% | $541.60M | 6.43x | 1.78 | United States | 34 |
| DCO | DUCOMMUN INC | NYSE | Aerospace & Defense | A | $1.35B | $90.45 | -1.01% | $98.47M | 38.16x | 0.63 | United States | 43 |
| LMB | LIMBACH HOLDINGS INC | NASDAQ | Engineering & Construction | A | $1.25B | $107.85 | -3.96% | $63.54M | 34.79x | 1.01 | United States | 57 |
| EVER | EVERQUOTE INC | NASDAQ | Internet Content & Information | A | $859.51M | $23.54 | -1.05% | $54.06M | 18.11x | 0.42 | United States | 54 |
| NRDS | NERDWALLET INC | NASDAQ | Internet Content & Information | A | $795.79M | $10.68 | 3.79% | $51.20M | 27.38x | 0.28 | United States | 55 |
| AKBA | AKEBIA THERAPEUTICS INC | NASDAQ | Biotechnology | A | $777.40M | $2.96 | -1.99% | $10.87M | -13.45x | 11.62 | United States | 28 |
| TBPH | THERAVANCE BIOPHARMA INC | NASDAQ | Biotechnology | A | $702.54M | $13.95 | -0.71% | $48.42M | 55.80x | 0.90 | Cayman Islands | 39 |
| KMDA | KAMADA LTD | NASDAQ | Drug Manufacturers - Specialty & Generic | A | $410.59M | $7.14 | 1.13% | $34.21M | 21.64x | 0.42 | Israel | 51 |
| ELMD | ELECTROMED INC | NYSEMKT | Medical Devices | A | $204.30M | $24.47 | -1.77% | $11.32M | 27.49x | 0.25 | United States | 44 |
Upgrade to Premium to View More
Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More
Already have access to Premium? Sign In
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.